{"entity":{"id":"fight-302","kind":"trial","name":"FIGHT-302","aka":[],"tldr":"FIGHT-302 set out to test whether the FGFR2 inhibitor pemigatinib should be used before chemotherapy in bile duct cancers driven by an FGFR2 fusion; the trial was stopped before it could answer the question.","summary":"Pemigatinib was approved in 2020 for previously treated cholangiocarcinoma with an FGFR2 fusion or rearrangement on the single-arm FIGHT-202 study. FIGHT-302 was the confirmatory phase 3 trial, randomising patients with untreated, unresectable or metastatic FGFR2-rearranged cholangiocarcinoma to pemigatinib or to gemcitabine and cisplatin, with progression-free survival as the primary endpoint.\n\nThe trial is recorded as terminated on ClinicalTrials.gov after enrolling 167 patients and has not reported an efficacy comparison, so the first-line question for FGFR inhibitors in this disease remains open.","status":"withdrawn","asOf":"2026-09-17","links":[{"label":"ClinicalTrials.gov NCT03656536","url":"https://clinicaltrials.gov/study/NCT03656536"}],"tags":["subtype-trials"],"related":[],"cancers":["cholangiocarcinoma","intrahepatic-cholangiocarcinoma","biliary-tract-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["pemigatinib","gemcitabine-cisplatin"],"companies":["incyte"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["tanios-bekaii-saab"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03656536","phase":"3","setting":"Untreated advanced cholangiocarcinoma with an FGFR2 rearrangement: pemigatinib against gemcitabine and cisplatin","sponsor":"Incyte","enrolled":167,"outcomes":[]},"route":"/trials/fight-302/","neighbours":{"cancer":[{"id":"biliary-tract-cancer","kind":"cancer","name":"Biliary tract cancer (all types)","route":"/cancers/biliary-tract-cancer/"},{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"},{"id":"intrahepatic-cholangiocarcinoma","kind":"cancer","name":"Intrahepatic cholangiocarcinoma","route":"/cancers/intrahepatic-cholangiocarcinoma/"}],"drug":[{"id":"gemcitabine-cisplatin","kind":"drug","name":"Gemcitabine + cisplatin","route":"/drugs/gemcitabine-cisplatin/"},{"id":"pemigatinib","kind":"drug","name":"Pemigatinib","route":"/drugs/pemigatinib/"}],"company":[{"id":"incyte","kind":"company","name":"Incyte","route":"/companies/incyte/"}],"person":[{"id":"tanios-bekaii-saab","kind":"person","name":"Tanios Bekaii-Saab","route":"/people/tanios-bekaii-saab/"}]}}